Soft tissue sarcomas present significant challenges in diagnosis and treatment due to their over 100 types. Current trials often combine different sarcoma types to gather data.

Tyrosine kinase inhibitors show promise, especially when paired with anthracyclines. New treatment combinations are needed due to existing therapies' toxicity.

Targeted therapies, including Trastuzumab Deruxtecan, and gamma secretase inhibitors for desmoid tumors are explored, highlighting the need for subtype-specific therapies for better patient outcomes.